Making trade-offs explicit: development and pilot of a Belgian MCDA framework for orphan drug appraisal.
A new decision-making framework brings transparency and consistency to rare-disease drug approval discussions.
The abstract reports this study presents the first MCDA framework for orphan drug reimbursement in Belgium and illustrates how criterion weights and scores can structure committee deliberation, complemented by contextual appraisal, to support more transparent, consistent, and accountable decision making. This PubMed record was retained because it is relevant to other.
What the study was
- Study design
- Narrative review
- Category
- Other
- Maturity
- Exploratory
- Journal
- International journal of technology assessment in health care
Why it surfaced
Narrative review relevant to Rare diseases with high unmet need; scored conservatively from the PubMed abstract.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.